BioStem Technologies, Inc. (OTCMKTS:BSEM - Get Free Report) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 137,800 shares, a growth of 17.1% from the November 30th total of 117,700 shares. Based on an average daily volume of 120,600 shares, the short-interest ratio is currently 1.1 days.
BioStem Technologies Price Performance
BSEM traded down $0.17 on Friday, reaching $12.65. The company's stock had a trading volume of 24,767 shares, compared to its average volume of 38,335. BioStem Technologies has a 1 year low of $4.41 and a 1 year high of $28.26. The business's 50 day moving average is $15.84 and its 200 day moving average is $12.06. The stock has a market cap of $210.28 million, a price-to-earnings ratio of 18.60 and a beta of -0.62.
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.31 by $0.01. The company had revenue of $82.56 million for the quarter, compared to the consensus estimate of $78.22 million. As a group, research analysts forecast that BioStem Technologies will post 1.41 earnings per share for the current fiscal year.
About BioStem Technologies
(
Get Free Report)
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Further Reading
Before you consider BioStem Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.
While BioStem Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
